Search research articles
Contact Us
Filters
Showing results (21-30 of 79) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
February 27, 2015
The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials
R Kumar, E Geuna, V Michalarea, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 25, 2014
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines
M Puglisi, P Thavasu, A Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2000
Metastatic extragonadal seminoma associated with cardiac transplantation
J S de Bono, J A Fraser, F Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2011
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
A W Tolcher, D I Quinn, A Ferrari, et al.
BJU International
|
June 26, 2003
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre
B Pamenter, J S De Bono, I L Brown, et al.
British Journal of Cancer
|
July 29, 2010
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
A T Brunetto, D Sarker, D Papadatos-Pastos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
D Bianchini, D Lorente, A Rodriguez-Vida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
C N Sternberg, J S de Bono, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 25, 2014
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
D Lorente, J Mateo, A J Templeton, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 79) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
February 27, 2015
The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials
R Kumar, E Geuna, V Michalarea, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 25, 2014
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines
M Puglisi, P Thavasu, A Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2000
Metastatic extragonadal seminoma associated with cardiac transplantation
J S de Bono, J A Fraser, F Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2011
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
A W Tolcher, D I Quinn, A Ferrari, et al.
BJU International
|
June 26, 2003
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre
B Pamenter, J S De Bono, I L Brown, et al.
British Journal of Cancer
|
July 29, 2010
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
A T Brunetto, D Sarker, D Papadatos-Pastos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
D Bianchini, D Lorente, A Rodriguez-Vida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
C N Sternberg, J S de Bono, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 25, 2014
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
D Lorente, J Mateo, A J Templeton, et al.
Page
of 8